Navigation Links
Researchers discover a switch that controls stem cell pluripotency
Date:9/15/2011

TorontoScientists have found a control switch that regulates stem cell "pluripotency," the capacity of stem cells to develop into any type of cell in the human body. The discovery reveals that pluripotency is regulated by a single event in a process called alternative splicing.

Alternative splicing allows one gene to generate many different genetic messages and protein products. The researchers found that in genetic messages of a gene called FOXP1, the switch was active in embryonic stem cells but silent in "adult" cellsthose that had become the specialized cells that comprise organs and perform functions.

"It opens the field to the fact that alternative splicing plays a really important role in stem cell pluripotency," said Prof. Benjamin Blencowe, principal investigator on the study and a Professor in the University of Toronto's Departments of Molecular Genetics and Banting and Best Department of Medical Research. "We're beginning to see an entirely new landscape of regulation, which will be crucial to our understanding of how to produce more effective pluripotent stem cells for therapeutic and research applications."

The findings were published in the current online edition of the scientific journal Cell.

Alternative splicing works by allowing different segments of genetic messages, also known as messenger RNAs, to be spliced in different combinations as the messages are copied from a gene's DNA. Those combinations make different messenger RNAs, which in turn become different proteins.

In stem cells, scientists have shown that a core set of proteins called transcription factors control pluripotency.

The splicing event discovered by Blencowe's team, including first author on the study Dr. Mathieu Gabut, changes the DNA binding properties of FOXP1 in a way that then controls the expression of the core pluripotency transcription factors, to facilitate maintenance of pluripotency. "As a mechanism that controls those core transcription factors, it's right at the heart of the regulatory process of pluripotency," said Blencowe.

At the same time, the mechanism represses the genes required for differentiationthe process whereby by a stem cell loses "stemness" and becomes a specific cell type that makes up an organ or performs a function.

As well, in collaboration with colleagues including Profs. Jeff Wrana and Andras Nagy in the Samuel Lunenfeld Research Institute at Mount Sinai Hospital, also Professors in U of T's Department of Molecular Genetics, the splicing switch identified by Blencowe's team was shown to play a role in "reprogramming," a potentially therapeutic technique in which researchers coax adult cells back into induced pluripotent stem cells by introducing the core transcription factors. "That's an important area in the field where we need better understanding because reprogramming, especially with human cells, is very inefficient," said Blencowe. "Often when reprogrammed stem cells are not fully reprogrammed they become tumorigenic and can lead to cancer."

Potential applications for stem-cell science include growing cells and tissues to test new drugs or to repair or replace damaged tissues in many diseases and conditions, including heart disease, diabetes, spinal cord injury and Alzheimer's disease.

As well, a better understanding of the mechanisms that regulate pluripotency, cell division and differentiation will provide knowledge of how diseases like cancer arise and suggest more targeted therapeutic approaches.

Blencowe and his lab have recently turned their attention to what might be controlling the factors that control both alternative splicing and the maintenance of stem-cell pluripotency. They have, said Blencowe, a few tantalizing glimpses. "There's still a lot to figure out, but I personally believe there is huge potential in the future. If we can fully understand the regulatory controls that allow us to make uniform populations of fully reprogrammed stem cells, there's no reason why they shouldn't be effective for many different therapies. It will come."


'/>"/>

Contact: Jim Oldfield
jim.oldfield@utoronto.ca
416-946-8423
University of Toronto
Source:Eurekalert

Related biology news :

1. MU researchers unveil new method for detecting lung cancer in Nature article
2. Notre Dame researchers demonstrate antibiotic sensing event central to MSRA antibiotic resistance
3. Researchers uncover a potential new benefit of pure maple syrup on liver health
4. EPA grants help Wayne State researchers stave off Great Lakes environmental invaders
5. UTHealth, BCM researchers find common gene variant associated with aortic dissection
6. Researchers find high levels of toxic PCBs in Indiana Harbor and Ship Canal
7. UH researchers work to develop screening method for superbug
8. Researchers find hormone that predicts premature death in kidney patients
9. Chinese researchers identify insect host species of a famous Tibetan medicinal fungus
10. Researchers publish study on neuronal RNA targeting
11. Researchers identify new drug target that stimulates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2016)... Nov. 29, 2016 BioDirection, a privately held ... for the objective detection of concussion and other traumatic ... successfully completed a meeting with the U.S. Food and ... test Pre-Submission Package. During the meeting company representatives reviewed ... a precursor to commencement of a planned pilot trial. ...
(Date:11/28/2016)... 28, 2016 "The biometric ... 16.79%" The biometric system market is in the ... the near future. The biometric system market is expected ... at a CAGR of 16.79% between 2016 and 2022. ... biometric technology in smartphones, rising use of biometric technology ...
(Date:11/22/2016)... 22, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... and Life Sciences Awards as "Most Outstanding in ... unprecedented year of recognition and growth for MedNet, which ... years. iMedNet ™ , MedNet,s ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... More than $4.3 million was raised last night ... ). The gala was held at the American Museum of ... and honored Alan Alda and P. ... medicine and the public understanding of science. Since the first ... has raised $40 million for the Laboratory,s research and education ...
(Date:12/2/2016)... ... December 01, 2016 , ... ACEA Biosciences, Inc. announced today ... clinical trials for AC0010 at the World Conference on Lung Cancer 2016, taking place ... on the phase I/II clinical trials for AC0010 in patients with advanced non-small cell ...
(Date:12/2/2016)... (PRWEB) , ... December 01, 2016 , ... DrugDev ... industry-wide collaboration, standardization and a beautiful technology experience. All three tenets were on display ... 100 clinical trial leaders from over 40 sponsor, CRO and site organizations to discuss ...
(Date:12/2/2016)... The immunohistochemistry (IHC) market is projected to reach USD ... the forecast period of 2016 to 2021 dominated by immunohistochemistry (IHC) ... largest share of immunohistochemistry (IHC) market, by end user.   ... , , ... 225 pages, profiling 10 companies and supported with 181 tables and ...
Breaking Biology Technology: